74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
74%
of retail investor accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Avidity Biosciences Inc
Closed
SectorHealthcare
15.05 4.51
Overview
Share price change
24h
Min
15.05
Max
15.05
Income | -63M -237M |
|---|---|
Sales | -12M 860K |
EPS | -1.27 |
Profit margin | -27,569.884 |
Employees | 511 |
EBITDA | -59M -232M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | -0.1% downside |
Market Cap | -9B 2.3B |
|---|---|
Previous open | 10.54 |
Previous close | 15.05 |
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
Avidity Biosciences Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Avidity Biosciences Inc Forecast
Price Target
By TipRanks
-0.1% downside
12 Months Forecast
Average 72.75 USD -0.1%
High 75 USD
Low 72 USD
Based on 4 Wall Street analysts offering 12 month price targets forAvidity Biosciences Inc - Dist in the last 3 months.
Financials
$
About Avidity Biosciences Inc
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Live chat